A 2015 study comparing schizophrenia patients who received oral or injectable antipsychotic medications found no difference in relapse rates between the groups. Now, a follow-up study published August ...
This transcript has been edited for clarity. Oliver Freudenreich, MD: Hello. I am Dr Oliver Freudenreich. For this Care Cues conversation today, I'm joined by my colleague, Dr Corinne Cather. We're ...
JACKSONVILLE, Fla. — For many, the holiday season brings celebration, travel and time with loved ones. But for people in recovery from substance use, it can also bring disrupted routines, heightened ...
The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...
Relapse prevention is why most people seek treatment, and with opioid use disorders (OUDs), there’s about a 90 percent relapse rate. This article explains why and how specific sayings from self-help ...
Alcohol use disorder (AUD) is one of the leading causes of preventable death in the United States and worldwide, and leads to substantial disease and medical complications. While treatments are ...
John F. Kelly, PhD, of the Recovery Research Institute and Department of Psychiatry at Mass General Brigham, is the lead ...
Researchers have found in a new study that integrating mobile chat–based messaging into existing smoking cessation programs ...
Submission is based on long-term Phase 3 data demonstrating 63 percent reduction in risk of relapse in adults with schizophrenia compared to placebo CAPLYTA ® is FDA approved to treat schizophrenia ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results